Cargando…

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diana, Anna, Carlino, Francesca, Franzese, Elisena, Oikonomidou, Olga, Criscitiello, Carmen, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225917/ https://www.ncbi.nlm.nih.gov/pubmed/32235297 http://dx.doi.org/10.3390/cancers12040819

Ejemplares similares

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
por: Carlino, Francesca, et al.
Publicado: (2022)

Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
por: Diana, Anna, et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives
por: Tirino, Giuseppe, et al.
Publicado: (2018)

Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis
por: Iovino, Francesco, et al.
Publicado: (2022)

Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
por: Pompella, Luca, et al.
Publicado: (2020)

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
por: Orditura, Michele, et al.
Publicado: (2007)

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
por: Carlino, Francesca, et al.
Publicado: (2022)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
por: Laterza, Maria Maddalena, et al.
Publicado: (2021)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015)

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions
por: Petrillo, Angelica, et al.
Publicado: (2019)

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
por: Riccardi, Ferdinando, et al.
Publicado: (2018)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
por: Ciaramella, Vincenza, et al.
Publicado: (2019)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
por: Orditura, Michele, et al.
Publicado: (2016)

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
por: Mehanna, Joe, et al.
Publicado: (2019)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
por: Medina, Mauricio A., et al.
Publicado: (2020)

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience
por: Galizia, Gennaro, et al.
Publicado: (2017)

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
por: Petrillo, Angelica, et al.
Publicado: (2020)

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
por: Ribeiro, Rita, et al.
Publicado: (2022)

NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS
por: Zito Marino, Federica, et al.
Publicado: (2023)

CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
por: LIETO, EVA, et al.
Publicado: (2015)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer
por: Nunziata, Carmine, et al.
Publicado: (2019)

Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions
por: Montella, Liliana, et al.
Publicado: (2021)

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma
por: Andolfo, Immacolata, et al.
Publicado: (2011)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer
por: Guo, Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_abosid29vi3misrlh8ee168ed4